Multiple myeloma drug Darzalex (daratumumab) will enter the clinical field next month after successfully expanding its coverage.

As new drugs such as bispecific antibody-based therapies are becoming the last treatment option in Korea, Darzalex’s success in expanding coverage has raised the prospect that combination therapy could emerge as the standard of care.

# According to industry sources on the 18th, the National Health Insurance Service and Janssen Korea recently completed drug pricing negotiations on the multiple myeloma drug Darzalex for its reimbursement extension.

Multiple myeloma is highly resistant and refractory to existing therapies and relapses frequently. Pa